Elucidating the trafficking mechanisms of effector proteins to the Plasmodium infected red blood cell
Elucidating the trafficking mechanisms of effector proteins to the Plasmodium infected red blood cell
批准号:
10319936
负责人:
Vasant Muralidharan
金额:
$37.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-01-05 至 2023-12-31
关键词:
AffectAntimalarialsBindingBiochemicalBiological AssayBiotinBlood VesselsBlood capillariesBrainCell membraneCellsCellular MembraneCessation of lifeClinicalCoagulation ProcessComplexCytolysisCytoplasmDataDestinationsDiseaseDrug TargetingDrug resistanceElementsEndoplasmic ReticulumEndothelial CellsErythrocytesEventFlow CytometryGenesGeneticGlycine decarboxylaseGoalsGrowthHabitatsHeat-Shock Proteins 70HomeHumanImmunofluorescence MicroscopyInfectionLabelLeadLigaseLipidsLocationMalariaMalaria VaccinesMass Spectrum AnalysisMeasuresMembraneMetabolismModelingMolecularMolecular ChaperonesMovementNutrientParasitesParasitic DiseasesPathway interactionsPeptide Signal SequencesPermeabilityPersonsPlasma CellsPlasmodiumPlasmodium falciparumPlastidsProcessPropertyProtein Export PathwayProtein SortingsProteinsPublishingResearchResistanceResistance developmentRoleRouteSignal TransductionSiteSorbitolSorting - Cell MovementSumTestingTimeTransmembrane DomainUsher ProteinsVacuoleVesiclebaseconditional mutantdrug developmenthuman diseaseknock-downmembermutantnovelnovel therapeuticsobligate intracellular parasiteplasmepsinprogramsprotein transportreceptorresistant strainscreeningsecretory proteintraffickingvesicle transport
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Plasmodium falciparum is a deadly human parasite that causes malaria and is responsible for nearly 450,000
deaths every year. Malaria is endemic in large regions of the world, home to about 4 billion people and it
affects ~250 million people annually. There are no effective vaccines against malaria and antimalarial drugs
are the mainstay of treatment. At this time, the parasite has gained resistance to all clinically available
antimalarial drugs and these drug-resistant strains are spreading throughout the world, threatening all the
progress that has been made against this disease in the last decade. Therefore, it is imperative that we
constantly generate new drugs and identify potential drug targets to stay ahead of this nefarious disease. The
clinical manifestations of this devastating parasitic disease, including death, are caused by the growth of P.
falciparum within the host red blood cell (RBC). To build a suitable habitat for growth inside RBCs, the malaria
parasite completely transforms the host cell. It changes the metabolism of the RBC, makes the RBC more rigid
such that it is harder for the infected RBC to pass through capillaries, modifies the RBC membrane to allow for
favorable movement of nutrients, and alters the binding properties of the RBC so that the infected cell can bind
to the endothelial cells lining blood vessels. The sum of these changes leads to disease and death, for
instance, binding of the P. falciparum infected RBC to endothelial cells can clog blood vessels in the brain
leading to clots that eventually result in death. The subjugation of the infected RBC is accomplished through
the action of several hundred proteins that the parasite transports to the host cell via poorly understood
mechanisms. The export of parasite effector proteins is essential for transforming the RBC and therefore, for
causing disease. Parasite effector proteins that are synthesized in the parasite cytoplasm need to be
transported across three or four cellular membranes in order to reach their site of action in the host RBC. The
molecular mechanisms that recognize, sort, and transport these parasite effectors to the infected RBC remain
to be identified. The proposed studies aim to unravel the molecular processes that govern key early events that
set parasite effectors on the path to the host RBC. We will pursue two aims to accomplish this goal. First, we
will generate conditional mutants of proteins in the endoplasmic reticulum of the parasite that are potentially
required for export of parasite effectors. The mutants will be analyzed using genetic, cellular, and biochemical
approaches to determine their roles in the export of parasite proteins. Second, we will take an unbiased
interactome screening approach that uses a proximity-based labeling approach and discover proteins that
usher exported proteins to their site of action in the host RBC. Attaining the objectives of the research program
will reveal key and unique protein trafficking mechanisms of P. falciparum that may be targeted for antimalarial
drug development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Exocytosis of Plasmodium egress and invasion organelles
-
批准号:10888455
-
项目类别:
-
资助金额:$54.02万
-
财政年份:2023
-
负责人:Vasant Muralidharan
-
依托单位:
Elucidating the trafficking mechanisms of effector proteins to the Plasmodium infected red blood cell
-
批准号:10411532
-
项目类别:
-
资助金额:$6.42万
-
财政年份:2022
-
负责人:Vasant Muralidharan
-
依托单位:
Essential function of a putative glycosyltransferase in P. falciparum
-
批准号:10382321
-
项目类别:
-
资助金额:$22.65万
-
财政年份:2021
-
负责人:Vasant Muralidharan
-
依托单位:
Essential function of a putative glycosyltransferase in P. falciparum
-
批准号:10215886
-
项目类别:
-
资助金额:$18.88万
-
财政年份:2021
-
负责人:Vasant Muralidharan
-
依托单位:
Diversity Supplement for Elucidating the trafficking mechanisms of effector proteins to the Plasmodium infected red blood cell
-
批准号:10077624
-
项目类别:
-
资助金额:$6.42万
-
财政年份:2018
-
负责人:Vasant Muralidharan
-
依托单位:
Role of Clp proteins in the biogenesis of the malaria parasite plastid
-
批准号:9226266
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2016
-
负责人:Vasant Muralidharan
-
依托单位:
ROLE OF CHAPERONES IN MAINTAINING THE ASPARAGINE REPEAT-RICH PROTEOME OF P. FALCI
-
批准号:8281043
-
项目类别:
-
资助金额:$3.69万
-
财政年份:2012
-
负责人:Vasant Muralidharan
-
依托单位:
ROLE OF CHAPERONES IN MAINTAINING THE ASPARAGINE REPEAT-RICH PROTEOME OF P. FALCI
-
批准号:8616715
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2012
-
负责人:Vasant Muralidharan
-
依托单位:
ROLE OF CHAPERONES IN MAINTAINING THE ASPARAGINE REPEAT-RICH PROTEOME OF P. FALCI
-
批准号:8590831
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2012
-
负责人:Vasant Muralidharan
-
依托单位:
海外基金